Clinical Trial Update: Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 study of LY2886721 for mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease was terminated; results have been post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• LY2886721

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer's Disease | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-05-18